10-Q: Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Lisata Therapeutics reported a net loss of $5.4 million for the first quarter of 2024, while continuing to advance its clinical programs.

Summary

• Lisata Therapeutics, a clinical-stage pharmaceutical company, reported a net loss of $5.4 million for the three months ended March 31, 2024, compared to a net loss of $6.2 million for the same period in 2023.
• The company's operating expenses totaled $6.6 million for the quarter, a slight decrease from $6.8 million in the prior year.
• Research and development expenses were $3.2 million, consistent with the prior year, while general and administrative expenses decreased to $3.4 million from $3.7 million.
• The company's cash, cash equivalents, and marketable securities totaled $43.3 million as of March 31, 2024.
• Lisata is focused on developing certepetide, a drug designed to enhance the delivery of anti-cancer therapies to solid tumors.
• Certepetide is currently being evaluated in multiple Phase 2 clinical trials across various solid tumor types.
• The company is also exploring out-licensing opportunities for other assets in its portfolio.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive aspects such as the decrease in net loss and the advancement of clinical trials, the company is still operating at a loss and faces significant risks related to funding and development. The sentiment is neutral to slightly negative due to the ongoing financial challenges.

Positives

• The net loss decreased by $0.8 million compared to the same quarter last year.
• Operating expenses saw a slight decrease, indicating cost management.
• The company maintains a solid cash position of $43.3 million.
• The company is actively advancing its lead drug candidate, certepetide, through multiple Phase 2 clinical trials.
• The company successfully sold New Jersey net operating losses for $0.7 million, generating a tax benefit.
• The company has a broad intellectual property portfolio with out-licensing opportunities.

Negatives

• The company continues to operate at a loss, with a net loss of $5.4 million for the quarter.
• The company is reliant on future capital raises to fund operations.
• The company has a history of operating losses and liquidity challenges.
• The company is subject to limitations on the amount of equity it can sell under its ATM agreement due to its public float.
• The company incurred a $0.1 million loss on the sale of New Jersey net operating losses.
• The company expensed a $0.1 million investment in Impilo Therapeutics.

Risks

• The company's ability to obtain sufficient capital to fund operations and expansion plans is a significant risk.
• The company's success depends on the clinical development and commercialization of its product candidates.
• The company faces risks related to regulatory approvals, market acceptance, and competition.
• The company's history of operating losses and liquidity challenges may make it difficult to raise capital.
• The company is subject to the risk of delays in clinical trials due to various factors.
• The company's ability to maintain and protect its intellectual property is crucial.
• The company is subject to the risk of potential future public health crises impacting its business.

Future Outlook

The company expects to use existing cash balances, marketable securities, and other means to meet its short and long-term liquidity needs, including potential issuances of debt or equity securities, partnerships, collaborations, and asset sales. The company believes its cash on hand and marketable securities will enable it to fund operating expenses for at least the next 12 months.

Management Comments

• The company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience.
• The company's goal is to develop and commercialize products that address important unmet medical needs.

Industry Context

Lisata Therapeutics is operating in the competitive pharmaceutical industry, specifically in the oncology space. The company is focused on developing innovative therapies for solid tumors, which is a significant area of unmet medical need. The company's approach of enhancing drug delivery through the CendR pathway is a novel approach that could differentiate it from competitors. The company is also exploring out-licensing opportunities, which is a common strategy in the biotech industry to generate revenue and partnerships.

Comparison to Industry Standards

• The company's reported net loss of $5.4 million is typical for a clinical-stage biotech company that is still in the development phase and not yet generating revenue from product sales.
• The company's cash position of $43.3 million is relatively modest compared to larger pharmaceutical companies, but it is sufficient to fund operations for at least the next 12 months.
• The company's focus on certepetide and its novel mechanism of action is a differentiating factor compared to other companies developing traditional cancer therapies.
• The company's clinical trial results for certepetide in pancreatic cancer, showing a 59% Objective Response Rate (ORR) and a 79% Disease Control Rate (DCR), are promising when compared to the 23% ORR and 48% DCR observed in the MPACT trial for standard-of-care chemotherapy.
• The company's strategy of co-administering certepetide with existing anti-cancer therapies is a faster-to-market approach compared to developing new chemical entities.

Management Changes

Legal Proceedings

• The company entered into a settlement agreement with Lingmed, requiring a payment of $0.5 million and a percentage of future milestone payments.
• The court entered a dismissal with prejudice of the action with Lingmed.

Stakeholder Impact

• Shareholders may be concerned about the company's ongoing losses and the need for additional capital.
• Employees may be affected by potential changes in the company's financial situation.
• Customers and partners may be interested in the progress of the company's clinical trials and the potential for new therapies.
• Creditors may be monitoring the company's financial health and ability to meet its obligations.

Next Steps

• The company will continue to advance its clinical trials for certepetide.
• The company will explore out-licensing opportunities for other assets in its portfolio.
• The company will seek additional funding through various means, including potential issuances of debt or equity securities.
• The company will continue to seek grants for scientific and clinical studies from various governmental agencies and foundations.

Key Dates

Keywords

Certepetide, Clinical Trials, Pharmaceutical, Oncology, Solid Tumors, Drug Development, R&D, Biotechnology, LSTA1, Pancreatic Cancer